GXLV:LSE:LSE-SPDR® S&P® U.S. Health Care Select Sector UCITS ETF GBP (GBP)

ETF | Others |

Last Closing

USD 34.2325

Change

+0.47 (+1.40)%

Market Cap

USD 0.39B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 636.40B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B

ETFs Containing GXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.35% 59% D- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.35% 58% F 60% D-
Trailing 12 Months  
Capital Gain 9.20% 49% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.20% 47% F 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.03% 32% F 42% F
Dividend Return 0.03% 31% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.12% 55% F 70% C-
Risk Adjusted Return 0.26% 31% F 41% F
Market Capitalization 0.39B 65% D 56% F

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.